Remote support program helps decrease blood pressure, study finds

People with elevated blood pressure saw improvement after 12 weeks of a telehealth support program, with or without support from a dietitian, a Geisinger study found.
A research team led by Alexander Chang, M.D., Geisinger nephrologist, enrolled two groups of patients with high blood pressure in a remote support program delivered through web-based applications. Both groups were provided lifestyle guidance from the American Heart Association, and one group also participated in weekly calls with a dietitian.
Over the course of 12 weeks, the two groups saw a similar reduction in 24-hour systolic blood pressure. The group with access to dietitian support showed a greater reduction in systolic blood pressure while asleep, as well as increased self-reported physical activity, better dietary quality and more weight loss than the group using remote support alone.
Results were published in the Journal of the American Heart Association.
“These remotely delivered programs improved blood pressure in a manner similar to a blood pressure medication,” Dr. Chang said. “The interventions were low-cost and could be scaled to help larger groups of patients improve their blood pressure through lifestyle change.”
The research team will explore implementing similar remotely delivered programs to a larger patient population at Geisinger to improve blood pressure and reduce cardiovascular risk.
Story Source:
Materials provided by Geisinger Health System. Note: Content may be edited for style and length.

Read more →

COVID-19 lockdown did not lead to quieter offshore ocean, research shows

Life on land may have quieted down during the height of the pandemic, but far offshore the Atlantic Ocean was just as active as ever according to a new study from the University of New Hampshire. Researchers found that there was no significant change in the continental shelf’s underwater soundscape during the year 2020 — a surprising contrast to earlier reports of quieter coastal waters during that same timeframe.
“It’s fascinating that oceans are so dynamic and variable; different regions really have different personalities based on the natural and human interactions that happen within those waters,” said Jennifer Miksis-Olds, research professor and director of UNH’s Center for Acoustic Research and Education.
In the study, recently published in the Journal of the Acoustical Society of America Express Letters, researchers focused on seven offshore sites geographically spanning the Outer Continental Shelf from Virginia to Florida — places where hydrophones had been placed on the seabed in 2017 and then retrieved in 2021 as part of UNH’s Atlantic Deepwater Ecosystem Observatory Network. The data indicated that although the sound produced from commercial shipping vessels decreased, there was an increase in sound from other vessels, like fishing boats and pleasure crafts. The net result: no major difference in the underwater soundscape approximately 45-280 miles from the shoreline.
“Having that long-term time series was really critical because it allowed for direct comparison of years of data before COVID-19 hit,” said Miksis-Olds. “Acoustic measurements in the deep ocean are more scarce than in coastal waters, so this research provides another perspective on how the deep oceans were impacted — or not — by COVID-19.”
Researchers acknowledge that the findings are in direct contrast to other studies focused on waters closer to the shoreline but say that’s why it’s important to examine different aspects of the ocean environment before drawing any conclusions.
The research was supported by the U.S. Department of the Interior and the Bureau of Ocean Energy Management in partnership with the Office of Naval Research and NOAA.
The University of New Hampshire inspires innovation and transforms lives in our state, nation and world. More than 16,000 students from all 50 states and 71 countries engage with an award-winning faculty in top-ranked programs in business, engineering, law, health and human services, liberal arts and the sciences across more than 200 programs of study. A Carnegie Classification R1 institution, UNH partners with NASA, NOAA, NSF and NIH, and received $260 million in competitive external funding in FY21 to further explore and define the frontiers of land, sea and space.
Story Source:
Materials provided by University of New Hampshire. Note: Content may be edited for style and length.

Read more →

Researchers find treatment options for patients whose blood cancer relapses after CAR-T

Mount Sinai and Memorial Sloan Kettering Cancer Center (MSK) researchers have identified therapies that can help patients with the blood cancer multiple myeloma who try an immunotherapy known as CAR-T only to find their cancer coming back afterwards.
CAR-T, short for chimeric antigen receptor T-cell therapy, enlists immune cells called T cells to fight multiple myeloma by altering them in the lab so they can find and destroy cancer cells. It has been a revolutionary treatment for this deadly cancer, but some patients relapse after receiving CAR-T therapy and have no good treatment options afterward.
In a new study published in the journal Blood in November, the researchers studied a large group of multiple myeloma patients who were given several different therapies when they relapsed after receiving a type of CAR-T cell therapy called BCMA-directed CAR-T. This version of CAR-T cell therapy targets the BCMA protein on cancerous plasma cells in order to fight multiple myeloma.
The researchers found that other therapies that engage T cells, including bispecific antibodies and other types of CAR-T cell therapy, appear to have the most pronounced success in knocking down these relapsed patients’ cancer for the greatest length of time.
“The findings of this study will serve as a benchmark for future prospective clinical studies that intend to improve the outcomes of patients who progress after CAR-T,” said a senior author on the study, Samir Parekh, MD, Director of Translational Research in Multiple Myeloma and co-leader of the Cancer Clinical Investigation program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. “This is the first study to report outcomes of different therapeutic options given to a large cohort of patients who relapsed after anti-BCMA CAR-T therapy. This is one of the most urgent and unmet needs in myeloma patients and, therefore, of great interest to the hematology community.”
This retrospective study analyzed 79 patients’ disease characteristics, the treatments given after relapse, and the patients’ responses to the therapies. Patients’ median overall survival to date is about 18 months.
Stem cell transplants also showed some efficacy in these patients. Other drug combinations can also be used with variable efficacy based on the characteristics of individual patients’ cancer, the study found.
The patients were treated at The Tisch Cancer Institute and MSK.
“We’re encouraged that subsequent use of other novel immune therapies like a second CAR-T cell therapy or a bispecific antibody was feasible and led to durable responses in patients,” said Sham Mailankody, MBBS, Associate Attending Physician, MSK, and senior author on the paper. “We look forward to continuing this work and unlocking the full potential of immune therapies for patients with multiple myeloma.”
Story Source:
Materials provided by The Mount Sinai Hospital / Mount Sinai School of Medicine. Note: Content may be edited for style and length.

Read more →

Researchers offer roadmap for identifying new neuroprotective treatments by leveraging sex differences

A new study from UCLA researchers provides a strategy for finding treatments optimally tailored for women and men to prevent cognitive decline in aging as well as progression of neurodegenerative diseases by leveraging sex differences in the brain.
Aging is associated with cognitive decline and brain atrophy. Aging also confers a major risk for developing a neurodegenerative disease. Given the aging population, novel strategies are needed to identify neuroprotective therapeutics. The study of sex differences in brain aging and neurodegenerative diseases can reveal new candidate treatment targets tailored for women and men.
Understanding the role of sex chromosome gene expression in the brain in the context of waning sex hormones during aging is a new approach to identifying neuroprotective treatments.
Dr. Rhonda Voskuhl, Professor, and Dr. Yuichiro Itoh, Associate Researcher, in the Department of Neurology, have created a roadmap to identify novel neuroprotective treatments tailored for women and men that leverage known sex differences in brain aging and neurodegenerative diseases.
Previously, research pursuing treatments for neurodegenerative diseases ignored sex differences in the brain and pooled data together from males and females, taking a “one size fits all” approach. This could dilute out robust effects that exist in one sex but not the other at the clinical research level and fail to capitalize on known disease modifiers in the discovery of new treatment targets at the basic research level.
In their study, “The X factor in neurodegeneration,” Voskuhl and Itoh write that known sex differences in the brain as well as the effect of higher expression of certain X chromosome genes in females (XX) compared to males (XY) can be assessed for their role in neurodegeneration during aging, a stage of life characterized by loss of potentially neuroprotective hormones in females (estrogen in menopause) and males (testosterone in andropause). The study offers a roadmap for disentangling the contribution of these sex-specific factors, which can yield treatments optimized and targeted for each sex.
In the future, this roadmap can be used by researchers to discover targets on the X chromosome gene for development of modulatory treatments that prevent neurodegeneration and promote neural repair during brain aging.
“Given the aging population and lack of treatments to prevent cognitive decline during health and to reduce the risk for developing neurodegenerative diseases, it is now imperative to apply new strategies to identify neuroprotective treatments,” said Voskuhl, who also directs the UCLA Multiple Sclerosis Program. “Leveraging what is known about sex differences in multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease can reveal candidate treatment targets tailored for women and men affected by these conditions. Sex chromosome effects remain understudied and represent a promising frontier for discovery, particularly in the context of declining levels of sex hormones during menopause and andropause.”
Voskuhl discloses being an inventor on patents owned by UCLA that involve estriol and estrogen receptor beta ligand treatments to maintain cognitive function during aging and neurodegenerative disease. Itoh has no conflicts of interest to disclose.
Story Source:
Materials provided by University of California – Los Angeles Health Sciences. Note: Content may be edited for style and length.

Read more →

Monkeypox mutations cause virus to spread rapidly, evade drugs and vaccines, study finds

Monkeypox has infected more than 77,000 people in more than 100 countries worldwide, and — similar to COVID-19 — mutations have enabled the virus to grow stronger and smarter, evading antiviral drugs and vaccines in its mission to infect more people.
Now, a team of researchers at the University of Missouri have identified the specific mutations in the monkeypox virus that contribute to its continued infectiousness. The findings could lead to several outcomes: modified versions of existing drugs used to treat people suffering from monkeypox or the development of new drugs that account for the current mutations to increase their effectiveness at reducing symptoms and the spread of the virus.
Kamlendra Singh, a professor in the MU College of Veterinary Medicine and Christopher S. Bond Life Sciences Center principal investigator, collaborated with Shrikesh Sachdev, Shree Lekha Kandasamy and Hickman High School student Saathvik Kannan, to analyze the DNA sequences of more 200 strains of monkeypox virus spanning multiple decades, from 1965, when the virus first started spreading, to outbreaks in the early 2000s and again in 2022.
“By doing a temporal analysis, we were able to see how the virus has evolved over time, and a key finding was the virus is now accumulating mutations specifically where drugs and antibodies from vaccines are supposed to bind,” Sachdev said. “So, the virus is getting smarter, it is able to avoid being targeted by drugs or antibodies from our body’s immune response and continue to spread to more people.”
Needles in a haystack
Singh has been studying virology and DNA genome replication for nearly 30 years. He said the homology, or structure, of the monkeypox virus is very similar to the vaccinia virus, which has been used as a vaccine to treat smallpox. This enabled Singh and his collaborators to create an accurate, 3D computer model of the monkeypox virus proteins and identify both where the specific mutations are located and what their functions are in contributing to the virus becoming so infectious recently.

Read more →

One in five patients with rheumatoid arthritis in England were undiagnosed during the pandemic, study finds

The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests.
The study, published today in The Lancet Rheumatology journal by researchers from King’s College London, shows there could be as many as a fifth of new cases that have gone undiagnosed, with cases not jumping up above pre-2020 levels. This suggests many of these patients have not been seen by their GP or been reviewed by a hospital specialist. However, for patients who were diagnosed during the pandemic, there did not appear to be more delays in starting treatment.
The study evaluated the diagnosis and treatment of different types of arthritis in England during the first two years of the pandemic.
Rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis are autoimmune diseases that primarily affect the joints and spine. People with these conditions experience chronic pain which can limit their mobility. If diagnosis and treatment is delayed, these conditions can lead to chronic disability due to joint damage, impaired function, work absence, and reduced quality of life. Early diagnosis and treatment of these types of arthritis improves outcomes for patients. Once diagnosed, patients can start highly effective treatments to control symptoms and prevent irreversible damage.
Each year, the quality of care for people with rheumatoid arthritis is benchmarked through a process of national audit. These audits were paused during the pandemic, however, making comparisons of care challenging.
Researchers from King’s College London used OpenSAFELY, a highly secure health data platform, to determine how the diagnosis and management of arthritis was affected by the pandemic. From a study population of over 17 million people in England, they were able to evaluate care for 31,000 people with new diagnoses of arthritis between April 2019 and March 2022.
The results showed that the number of newly recorded arthritis diagnoses fell by 20% in the year after the first COVID-19 lockdown, relative to the year before the pandemic. Arthritis diagnoses fell again as COVID-19 cases rose, before returning to pre-pandemic levels by April 2022. Researchers did not see a rebound in diagnoses after restrictions were lifted, suggesting that there is likely to be a substantial burden of undiagnosed patients.
Importantly, the study also showed that, for people who were diagnosed during the pandemic, the time to assessment by a hospital specialist was shorter than before the pandemic. This may be due to fewer hospital referrals overall and increased utilisation of virtual appointments during the pandemic.
Additionally, the proportion of patients who were started on treatment was similar before and during the pandemic. However, medications perceived to be safer, but less effective, were prescribed more frequently during the pandemic. This could relate to clinicians’ concerns about the effects of stronger medications on COVID-19 infections.
Lead author Dr Mark Russell, from King’s College London, said: “This study highlights that there are likely to be people with joint pain and swelling who remain undiagnosed as a consequence of the pandemic. It is important to speak to a doctor if you have these symptoms, as early diagnosis and treatment of conditions such as rheumatoid arthritis greatly improves outcomes for patients and increases the likelihood of disease remission.
“An important message of this study is that it is possible to assess the quality of care for patients with long-term health conditions using routinely collected health data. This approach could be applied to many other chronic health conditions and be used to provide feedback to NHS organisations and clinicians, with the aim of optimising care for patients.”
Story Source:
Materials provided by King’s College London. Note: Content may be edited for style and length.

Read more →

Cutting the risk of stomach bleeding, occasionally caused by regular aspirin use

A new study, led by experts at the University of Nottingham found that the risk of stomach bleeding caused by using aspirin long-term, can be reduced with a short course of antibiotics, potentially improving the safety of aspirin when used to prevent heart attacks, strokes and possibly some cancers.
The results of the .HEAT (Helicobacter pylori Eradication Aspirin) trial, which was led by Professor Chris Hawkey from the University of Nottingham’s School of Medicine and Nottingham Digestive Diseases Centre, and funded by the National Institute for Health and Care Research Health Technology Assessment programme, are published in The Lancet.
Aspirin in low doses is a very useful preventative drug in people at high risk of strokes or heart attacks. However, on rare occasions, it can provoke internal ulcer bleeding.
By thinning the blood, aspirin makes ulcers in the stomach bleed. These ulcers may be caused by a particular type of bacteria, helicobacter pylori.
The STAR (Simple Trials for Academic Research) team from the University of Nottingham investigated whether a short course of antibiotics to remove these bacteria would reduce the risk of bleeding in aspirin users.
The .HEAT (Helicobacter pylori Eradication Aspirin) Trial was a very large trial conducted in 1,208 UK general practices. It was a real-life study which used clinical data routinely stored in GP and hospital records, instead of bringing patients back for follow up trial visits.
The team wrote to 188,875 patients who were taking aspirin and 30,166 volunteered and took part in the study. Those who tested positive for H. pylori were randomised to receive antibiotics or placebos (dummy tablets) and were followed for up to 7 years.
Over the first two and a half years, those who had antibiotic treatment were less likely to be admitted to hospital because of ulcer bleeding than those who had dummy tablets (6 versus 17). Protection occurred rapidly: with those who received placebos (dummy treatment), the first hospitalisation for ulcer bleeding occurred after 6 days, compared to 525 days following antibiotic treatment.
Over a longer time period, protection appeared to wane. However, the overall rate of hospitalisation for ulcer bleeding was lower than expected and this in line with other evidence that ulcer disease is on the decline. Risks for people already on aspirin are low. Risks are higher when people first start aspirin, when searching for H. pylori and treating it is probably worthwhile.
Professor Chris Hawkey said: “Aspirin has many benefits in terms of reducing the risk of heart attacks and strokes in people at increased risk. There is also evidence that it is able to slow down certain cancers. The .HEAT trial is the largest UK-based study of its kind, and we are pleased that the findings have shown that ulcer bleeding can be significantly reduced following a one-week course of antibiotics. The long-term implications of the results are encouraging in terms of safe prescribing.”
The results of the trial will be presented at the UEG (United European Gastroenterology) scientific meeting in Vienna where it has won a 10,000 Euro top abstract prize. The STAR team intend to use the prize to sponsor a competition to support a collaboration with a research team that would like to take advantage of STAR methodology.
Story Source:
Materials provided by University of Nottingham. Note: Content may be edited for style and length.

Read more →

Scientists define independent subtype of idiopathic multicentric Castleman disease

Idiopathic plasmacytic lymphadenopathy (IPL) is a clinical condition marked by an excessive amount of antibody production due to the proliferation of polyclonal plasma cells in the lymph nodes. At present, it is not clear if IPL is a subtype of idiopathic multicentric Castleman disease (iMCD)-not otherwise specified (NOS). In a new study, researchers from Okayama University have found clinicopathological evidence needed to establish a separate disease unit for IPL under iMCD-NOS.
Multicentric Castleman disease (MCD) comprises a heterogenous group of rare disorders that exhibit generalized symptoms such as swelling of lymph nodes, anemia, fever, and fatigue. The causative factors underlying MCD include Kaposi sarcoma-associated herpesvirus (KSHV)/ human herpesvirus 8 (HHV8) infections. KSHV/HHV8-negative MCD without association with the POEMS (polyneuropathy, organomegaly, endocrinopathy, M proteins, and skin changes) syndrome are termed “idiopathic,” i.e., diseases with no identifiable cause, and are thus referred to as “iMCD.” At present, specific clinical manifestations or diagnostic criteria have not been identified for iMCD, which often results in treatment delay.
iMCD is further classified as iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) and iMCD-NOS (not otherwise specified). With additional research efforts, iMCD-NOS, which is highly heterogenous, could be classified into various subtypes.
Interestingly, a disease known as idiopathic plasmacytic lymphadenopathy (IPL), which is characterized by hypergammaglobulinemia, i.e., high levels of serum immunoglobulins, and histologically mature plasma cell proliferation in the lymph nodes, is considered a part of iMCD-NOS due to their clinicopathological similarity. However, till date, no study has validated if IPL has distinct clinicopathologic features compared to other iMCD-NOS.
This motivated a team of researchers led by Assistant Professor Asami Nishikori, including Associate Professor Midori Filiz Nishimura, and Professor Yasuharu Sato from Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Japan to conduct a thorough clinicopathological examination of IPL and others in iMCD. Their findings were published on September 7, 2022, in the International Journal of Molecular Sciences.
“We wanted to determine whether IPL has distinct and uniform clinicopathologic features compared to other subtypes (non-IPL) in iMCD-NOS,” remarks Assist. Prof. Nishikori while discussing the motivation behind the study.
The team analyzed lymph node specimens derived from 42 Japanese patients with lymph node involvement of iMCD-NOS, who met the consensus diagnostic criteria of iMCD and were negative for KSHV/HHV8 infections. Upon further examination, the team classified 34 of the 42 patients as the IPL group and the remaining 8 as the non-IPL group. On grading histological features such as vascularity, plasmacytosis (high proportion of plasma cells), atrophic and hyperplastic germinal centers (GCs), the team identified significant pathological differences between the specimens of the IPL and non-IPL groups. The IPL group demonstrated greater plasmacytosis and hyperplastic GCs compared to the non-IPL group. Conversely, the vascularity of the non-IPL group was higher than that of the IPL group.
Clinically, the IPL group exhibited higher platelet count and serum antibody (immunoglobulin G) levels, with lesser fluid retention in pleural and/or abdominal cavity. The frequency of disease-specific autoantibody detection was also different between the groups.
In addition, the clinical course and treatment responses in the two groups were also distinct. Upon treatment with tocilizumab, an anti-interleukin 6 receptor monoclonal antibody approved to treat iMCD in Japan, there was a significant improvement in the condition of patients with IPL. In contrast, patients with non-IPL responded poorly to the drug and showed progressed disease activity, requiring more intensive treatment.
These findings were consistent with those of previous studies that suggest that the clinical course of IPL disease progression is slower as compared to the non-IPL group, and with a superior response to anti-IL-6 agents. Discussing these findings, Assist. Prof. Nishikori states “Given the heterogeneity of non-IPL cases, we must try to identify its primary cause. Molecular analysis could lead to a better understanding of disease pathology and the development of subsequent targeted therapies.”
To sum up, these findings have established IPL as a clinicopathologically uniform disease, which can be reclassified into an independent subtype of iMCD.
So, what are the future implications of these findings? “It is critical that patients get the most out of any treatment modules. Studies on iMCD subtype-specific diagnostic biomarkers, treatment, and follow-up are thus warranted in the future to improve the clinical outcomes for these patients,” concludes Assist. Prof. Nishikori.

Read more →

Study Shows New Covid Booster Improves Protection for Older People, Pfizer Says

Federal officials are hoping that the encouraging results will spur more Americans to get an updated booster before a feared surge in coronavirus cases this winter.WASHINGTON — A new study by Pfizer and BioNTech suggests that their updated coronavirus booster released in September is nearly four times as good as its predecessor at boosting antibodies against the currently dominant version of the virus for people over age 55.Federal officials are hoping that the encouraging results will bolster what has so far been a dismal public response to the retooled shots. Only about 8 percent of Americans ages 5 and up have received the new boosters from Pfizer and Moderna, which are recommended for people in that age group who have had an initial round of vaccination.Pfizer and BioNTech announced the study results in a news release. The companies said that one month after getting the new booster, clinical trial participants over 55 had antibody levels that were 3.8 times as high as those who received the original booster. The number of participants in the study was small, with 36 people receiving the new booster and 40 receiving the old one.The control group included only older adults, and the findings so far are limited to one month after the shot. Results from a similar clinical trial by Moderna are expected soon.Biden administration officials cast the results as good news in the battle against Covid-19, but whether many Americans will care much remains to be seen. As the pandemic nears the three-year mark, the public seems deeply weary of Covid vaccinations. In a Kaiser Family Foundation poll conducted in September, one in five adults said they had not even heard about the new boosters.Read More on the Coronavirus PandemicWarnings of a ‘Tripledemic’: An expected winter rise in Covid cases appears poised to collide with a resurgent flu season and a third pathogen straining pediatric hospitals in some states.Updated Boosters for Kids: The Food and Drug Administration broadened access to updated Covid booster shots to include children as young as 5.A Decline Among Seniors: Americans over 65 remain the demographic most likely to have received the original series of Covid vaccinations. But fewer are getting booster shots, surveys indicate.Personality Changes: New research suggests that Covid’s disruption of social rituals and rites of passage have made people less extroverted, creative, agreeable and conscientious.“Folks have just tuned out,” said Michael Fraser, the chief executive of the Association of State and Territorial Health Officials. “Which is totally unfortunate and not the place where you want to be.”Administration officials said the results of the study offered a new reason for Americans to seek out the updated shots before what experts fear could be a winter surge of the virus that leads to tens of thousands of unnecessary deaths.“You can see the train coming down the tracks,” said Dr. Peter Marks, the top vaccine regulator for the Food and Drug Administration. “The time to get off the tracks is now, not when you can smell the oil from the train engine.”Pfizer said study participants in the control group had been boosted about six months earlier, while those who received the updated shot had had their last booster 11 months earlier. Both groups had similar antibody levels before receiving the new booster.The updated shot targets the version of the virus that now looms largest in the United States, a subvariant of Omicron known as BA.5. But by next month, a new Omicron subvariant is expected to become dominant.Administration officials say those subvariants are structurally alike enough that the updated shots should continue to provide potent protection. Dr. Marks said that he expected some decrease in the boosters’ ability to neutralize the virus but their overall benefits to hold.While urging Americans to get the updated shots, Biden administration officials are not casting them as a final answer to the pandemic. For two years, the administration has been engaged in a continual game of catch-up. By the time scientists have revised the vaccine to protect against the virus’s newest incarnation, it has already shifted to another form.That reality, some experts said, could be part of the reason Americans are showing diminished enthusiasm for each added shot. So far, the administration has not persuaded Congress to allot more money to develop the next generation of vaccines that could end the behind-the-curve cycle.Asked whether positive clinical trial results would help pique interest in the boosters, Dr. Philip Huang, the health director for Dallas County in Texas, said, “Anything that provides some more reinforcement for people who are on the fence or delaying always helps.” But, he said, “if there is a bump-up in hospitalizations and serious illness, that’s when people start to take it seriously.”“It’s a shame that’s what it takes to get motivation up,” he added.Some public health experts say President Biden himself undermined any sense of urgency when he declared in a television interview in September that “the pandemic is over.” Last week, he tried to draw attention to the new shots by getting his own dose on camera.

Read more →

Voters Have Expanded Medicaid in 6 States. Is South Dakota Next?

Ten years after the Supreme Court ruled that states did not have to expand Medicaid, the politics are changing in states like South Dakota, where rural hospitals and nursing homes are struggling.CONDE, S.D. — Progressives have helped bring health coverage to tens of thousands of uninsured Americans with an exercise in direct democracy: They have persuaded voters to pass ballot measures expanding Medicaid in six states where Republican elected officials had long been standing in the way.Now comes the latest test of this ballot box strategy: South Dakota.An unlikely coalition of farmers, business leaders, hospital executives and clergy members have coalesced around Amendment D, a ballot measure that would enshrine Medicaid expansion in the South Dakota Constitution, over the objections of Gov. Kristi Noem, a Republican. It is widely expected to pass next week on Election Day.It has been 10 years since the Supreme Court ruled that states did not have to expand Medicaid — the government health insurance program for low-income people — under the Affordable Care Act, and the politics around the issue have shifted. Philosophical objections to large government programs are giving way to economic considerations, particularly in rural states like South Dakota, where struggling hospitals and nursing homes are eager for federal reimbursement dollars that come from Medicaid.If Medicaid expansion is adopted in South Dakota — a state where Donald J. Trump won more than 60 percent of the vote both times he ran — advocates say it will send a strong signal to other Medicaid expansion holdouts, like Texas and Florida. South Dakota is one of 12 remaining states that have not expanded, down from 19 in 2016.“It is harder and harder for conservative politicians to stand behind the idea that the A.C.A. is just one lawsuit away from being repealed or overturned,” said Kelly Hall, the executive director of the Fairness Project, a national nonprofit that is behind the “Yes on D” campaign.“Our work,” she said, “is about how do we build odd-bedfellows coalitions delivering the message that Medicaid expansion is good for the economy, brings back tax dollars to the states, is helpful for small businesses and is not just ‘Do you support Obamacare?’”In the tiny farming town of Conde, where a road sign puts the population at 140, that is exactly the argument that Doug Sombke, the president of the South Dakota Farmers Union, is making.Doug Sombke, the president of the South Dakota Farmers Union, is among the ballot measure’s supporters.Tim Gruber for The New York Times“Farmers and ranchers,” Mr. Sombke said, “are small-business men, and they just can’t afford insurance.”Tim Gruber for The New York TimesNationally, an estimated 2.2 million uninsured American adults fall into the Medicaid “coverage gap” because they live in one of the 12 states that refuse to expand the program. Too poor to qualify for subsidized private insurance through the Obamacare exchanges yet not poor enough for Medicaid, they rely on charity care — or skip care altogether.South Dakota officials estimate that 42,500 people would be newly eligible for Medicaid under an expanded program. Some of them are people Mr. Sombke represents. “Farmers and ranchers,” he said, “are small-business men, and they just can’t afford insurance.”The State of the 2022 Midterm ElectionsElection Day is Tuesday, Nov. 8.Biden’s Speech: In a prime-time address, President Biden denounced Republicans who deny the legitimacy of elections, warning that the country’s democratic traditions are on the line.State Supreme Court Races: The traditionally overlooked contests have emerged this year as crucial battlefields in the struggle over the course of American democracy.Democrats’ Mounting Anxiety: Top Democratic officials are openly second-guessing their party’s pitch and tactics, saying Democrats have failed to unite around one central message.Social Security and Medicare: Republicans, eyeing a midterms victory, are floating changes to the safety net programs. Democrats have seized on the proposals to galvanize voters.Four rural nursing homes have already closed this year in South Dakota, and a fifth is set to close by the end of this month. Additional federal reimbursement dollars, Mr. Sombke said, might help forestall future closures and prevent people in rural areas from having to drive 60 miles or more for care.He cited a state legislative analysis showing that South Dakota would save $162 million over five years by expanding Medicaid. Using numbers contained in that analysis, proponents of Amendment D have calculated that during the first year of the program, $328 million would flow back into the state from the federal government.“We’re talking about money that we’re sending to Washington — our own money that we pay, tax money that we’re letting other states use,” Mr. Sombke said. “I’m sorry, but that’s not conservatism. That’s just stupid.”Medicaid, created in 1965 under President Lyndon B. Johnson to provide health coverage to the poor, is jointly financed by states and the federal government. The Affordable Care Act, passed in 2010, initially required states to expand Medicaid to cover nearly all adults with incomes up to 138 percent of the poverty level, currently around $19,000 for an individual and $38,000 for a family of four. But the Supreme Court struck down the requirement in 2012.Congress intentionally made expansion a good deal for states, as the Affordable Care Act requires the federal government to pick up 90 percent of the cost for patients enrolled in the expansion program. When Congress passed the $1.9 trillion coronavirus relief package last year, it increased the incentives for states by offering an additional federal match for two years.Those new incentives have “reignited some of the discussion around expansion,” said Robin Rudowitz, an expert on Medicaid at the nonpartisan Kaiser Family Foundation. “Republicans who had not supported expansion for a long time are starting to think about it.”Among them is Greg Jamison, a South Dakota state representative and self-described fiscally conservative Republican who had previously opposed expanding Medicaid. Mr. Jamison represents part of Sioux Falls, which is home to two of the state’s largest health care organizations, Sanford Health and Avera Health. Both back Amendment D.Greg Jamison, a Republican state representative, said his discussions with uninsured relatives led him to conclude that expanding Medicaid was the right thing to do.Tim Gruber for The New York TimesOpponents of the ballot measure say the health systems, which have poured money into the campaign to pass it, do not need federal help. They note that the former chief executive of Sanford Health, who stepped down in 2020 amid controversy over his statement that he would not wear a mask after recovering from Covid-19, received a hefty payout, which Mr. Jamison acknowledged “doesn’t look good.”But the lawmaker said his discussions with uninsured relatives — “conversations that are bigger and more serious than any I’ve ever had,” he said — led him to conclude that expanding Medicaid was the right thing to do. Mr. Jamison also views expansion as a way to support new mothers in South Dakota, where abortion became illegal, with very limited exceptions, after the Supreme Court overturned Roe v. Wade in June. Now he appears in an ad for the proponents.“This is a risky conversation, since it’s not in our platform,” Mr. Jamison said over breakfast at a diner in downtown Sioux Falls. “But it just makes sense. It’s time to get over it.”The South Dakota ballot initiative would require the state to expand Medicaid eligibility by July 1, 2023. Ms. Noem, a rising star in the Republican Party who is running for re-election in a surprisingly competitive race, has said that if Amendment D passes, she will carry it out.Opponents, including the conservative group Americans for Prosperity, argue that Medicaid needs to be overhauled, not expanded. Keith Moore, the group’s South Dakota director, said that giving free health care to able-bodied people would discourage them from working and would hurt the truly needy by creating long lines for doctors.“With people being put on Medicaid, you’re taking purpose from people, you’re taking dignity from people,” Mr. Moore said. “People need to work.”But advocates say South Dakotans who need health care are already working; the state’s unemployment rate is 2.3 percent, the lowest figure in more than a decade. The prospect of new jobs is one reason the board of the South Dakota Chamber of Commerce and Industry voted to back Amendment D in September after a “healthy debate,” said David Owen, its president and chief lobbyist.“The infusion of money into the health care system will help stabilize and create health care jobs,” he said. “When you look at this in reality, you just have to come to the conclusion that we keep South Dakota money here.”Proponents of expansion are confident because there has already been a test vote. During the state’s primary election in June, voters rejected a ballot measure that would have required a majority of 60 percent to approve any constitutional amendment. That measure, known as Amendment C, was widely considered an effort by opponents of Medicaid expansion to thwart it.“They put all their eggs in one basket,” Mr. Owen said. “It didn’t work.”Once Amendment C failed, donations from Americans for Prosperity and other opponents dried up, said State Senator John Wiik, a Republican leading the fight against expansion. Referring to the state’s major health care organizations, he said, “I kind of feel like I’m up against three big old medical Goliaths, here all by myself.”A recent survey by South Dakota State University that found 53 percent of likely voters supported Medicaid expansion, 20 percent were opposed and 27 percent were undecided. The coalition backing the amendment, which calls itself South Dakotans Decide Healthcare, has raised more than $3 million, most of it from health care organizations, according to campaign finance filings. Mr. Wiik said his side had raised “absolutely zero.”Still, Mr. Wiik said he remained hopeful. He said Republicans in the state’s Legislature had taken steps to expand access to care by increasing reimbursement rates for health providers and helping the South Dakota Farm Bureau improve its health insurance offerings. (The Farm Bureau tilts Republican, while the farmers’ union leans Democratic.)“It’s not like the conservatives in South Dakota have just sat around and said, ‘No,’” Mr. Wiik said.In addition to making an economic case for expansion, advocates have tried to put a human face on the problem of the uninsured by enlisting ordinary South Dakotans to tell their stories.Sarah Houska left a job with the state to spend more time caring for one of her sons, who has serious health issues. Now, she works part time at a dental office and has no coverage.Tim Gruber for The New York TimesThey include people like Sarah Houska, 29, of Sioux Falls. A single mother of two, she left a job with the state — in which she determined whether people were eligible for Medicaid — to spend more time caring for one of her sons, who has serious health issues. Now, she works part time at a dental office and has no coverage. She also volunteers for the American Heart Association’s team working to pass Amendment D.“My dad is a die-hard Republican,” she said. “He was so against expansion until my personal situation. When you are faced with it and it’s family, it’s different.”The ballot initiative strategy, though, has its limits. Of the 12 remaining states that have not expanded Medicaid, just three — South Dakota, Florida and Wyoming — currently allow ballot initiatives. (Mississippi had a ballot initiative process until last year, when it was struck down by the state’s Supreme Court.)Advocates for expansion say their next target is North Carolina, where the power to take action rests in the hands of lawmakers. Republican leaders in the state’s General Assembly have reversed themselves and now express support for Medicaid expansion — using many of the same arguments about tax dollars and financial incentives that the Fairness Project, the national nonprofit running the campaign for Amendment D, is using in South Dakota.The group was created by a California health care workers’ union in 2015, when congressional Republicans were still trying to repeal the Affordable Care Act and state expansion efforts were stalled. Ms. Hall, the group’s executive director, said it had not been “nearly as difficult to have a conversation with voters as it would have been with conservative politicians in state legislatures.”In 2017, Maine voters rebuked their Republican governor, Paul LePage, by passing an expansion initiative, though it took the election of a Democrat, Gov. Janet Mills, to put it in place. In 2018, Idaho, Nebraska and Utah — all states that Mr. Trump had won handily two years earlier — passed ballot measures as well. So did Missouri and Oklahoma in 2020.“We are six for six, in places that you would not expect,” Ms. Hall said. “None of these places are bastions of progressive organizing.”

Read more →